Matthew Gumbleton, MD
Huntsman Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Matthew Gumbleton, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:03 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06124118 · Tumor Treating Fields for Locally Advanced NSCLCUniversity of Utah · withdrawn · Non Small Cell Lung Cancer · principal investigator
- Ph2NCT04163432 · Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLCUniversity of Utah · terminated · Non-Small Cell Lung Cancer Metastatic · principal investigator
- Ph1NCT04141644 · Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCUniversity of Utah · active not recruiting · Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.